Deferasirox effectively reduces iron overload in non-transfusion-dependent thalassemia (NTDT) patients: 1-year extension results from the THALASSA study
- First Online:
- Cite this article as:
- Taher, A.T., Porter, J.B., Viprakasit, V. et al. Ann Hematol (2013) 92: 1485. doi:10.1007/s00277-013-1808-z
- 1.5k Downloads
Patients with non-transfusion-dependent thalassemia (NTDT) often develop iron overload that requires chelation to levels below the threshold associated with complications. This can take several years in patients with high iron burden, highlighting the value of long-term chelation data. Here, we report the 1-year extension of the THALASSA trial assessing deferasirox in NTDT; patients continued with deferasirox or crossed from placebo to deferasirox. Of 133 patients entering extension, 130 completed. Liver iron concentration (LIC) continued to decrease with deferasirox over 2 years; mean change was −7.14 mg Fe/g dry weight (dw) (mean dose 9.8 ± 3.6 mg/kg/day). In patients originally randomized to placebo, whose LIC had increased by the end of the core study, LIC decreased in the extension with deferasirox with a mean change of −6.66 mg Fe/g dw (baseline to month 24; mean dose in extension 13.7 ± 4.6 mg/kg/day). Of 166 patients enrolled, 64 (38.6 %) and 24 (14.5 %) patients achieved LIC <5 and <3 mg Fe/g dw by the end of the study, respectively. Mean LIC reduction was greatest in patients with the highest pretreatment LIC. Deferasirox progressively decreases iron overload over 2 years in NTDT patients with both low and high LIC. Safety profile of deferasirox over 2 years was consistent with that in the core study.
KeywordsIron overload Iron chelation Non-transfusion-dependent thalassemia Deferasirox
In patients with non-transfusion-dependent thalassemias (NTDT), such as beta-thalassemia intermedia, alpha-thalassemia (mainly HbH disease), and mild/moderate forms of HbE/beta-thalassemia, iron overload is an important challenge in terms of diagnosis, monitoring, and treatment. Increased intestinal absorption of iron, caused by ineffective erythropoiesis, is the main cause of iron overload in these patients, which can become clinically relevant by the age of 10 years . Iron overload is associated with liver dysfunction and vascular, bone, and endocrine morbidities . A wealth of information on iron overload and its management is available from transfusion-dependent beta-thalassemia major. However, given the differences in iron metabolism, pathophysiology, and iron loading rate in patients with NTDT, a direct extrapolation cannot be made, making it important to investigate iron overload in NTDT [3, 4, 5, 6, 7, 8, 9, 10, 11].
THALASSA (assessment of Exjade® in non-transfusion-dependent THALASSemiA patients) is the first randomized, double-blind, placebo-controlled trial to assess deferasirox (Novartis Pharmaceuticals, East Hanover, NJ, USA) for investigational use in patients with NTDT . Results from the 1-year THALASSA study, the largest dataset to date in NTDT patients, showed that liver iron concentration (LIC) significantly decreased versus placebo [least-squares mean (LSM) ± standard error]: –2.33 ± 0.7 (p = 0.001) and −4.18 ± 0.69 mg Fe/g dry weight (dw) (p < 0.001) for deferasirox starting doses of 5 and 10 mg/kg/day, respectively . LIC increased by 0.38 mg Fe/g dw in patients receiving placebo . Patients treated with deferasirox had a similar frequency of overall adverse events (AEs) as patients treated with placebo .
In order to provide longer-term deferasirox data in NTDT patients and to assess whether a greater number of patients could reach the therapeutic goal of LIC <5 and <3 mg Fe/g dw than observed in the core study, a 1-year extension phase was carried out. This allowed assessment of up to 2 years of deferasirox treatment, the longest assessment of chelation in a controlled trial in NTDT patients, and the opportunity for patients treated with placebo in the core to receive deferasirox in the extension phase, as well as to provide further guidance on dosing and monitoring strategies.
THALASSA is a multinational, prospective, randomized, double-blind, placebo-controlled phase II study (27 centers across nine countries). Study design/inclusion/exclusion criteria have been described previously .
Patients randomized to deferasirox during the core (starting dose 5 or 10 mg/kg/day) and those receiving placebo had the option to enter a pre-planned, 1-year, open-label extension phase. Written, informed consent was required prior to extension entry. Patients with continuous increases in serum creatinine ≥33 % above baseline and above the upper limit of normal (ULN), alanine aminotransferase (ALT) >2× baseline and >5× ULN, or progressive proteinuria that did not improve after drug interruption/dose reduction in the core were excluded from entering the extension.
The study was conducted in accordance with Good Clinical Practice guidelines and the Declaration of Helsinki. The study was approved by local ethics committees of study sites. An independent data monitoring committee reviewed safety data and advised on study continuation and/or protocol changes.
The primary efficacy endpoint for the extension was the number and proportion of patients reaching LIC <5 mg Fe/g dw by the end of the extension. Additional analyses included assessment of the number and proportion of patients with LIC <3 mg Fe/g dw and the change in serum ferritin. LIC was measured at baseline then every 6 months using a validated R2 MRI technique (FerriScan®; Resonance Health, Perth, Australia) .
Secondary endpoints included correlation of serum ferritin with LIC and change in LIC and serum ferritin in patients who interrupted therapy as a result of LIC <3 mg Fe/g dw or serum ferritin <100 ng/mL.
Serum ferritin was measured at baseline then monthly or quarterly (depending on whether the patient was still receiving deferasirox). Mean iron excretion was calculated by adapting the Angelucci formula : mean iron excretion (mg/kg/day) = 10.6 × (change in LIC)/days (730).
Safety was evaluated through continuous monitoring and recording of AEs, laboratory testing, and clinical evaluations. For patients with LIC <5 mg Fe/g dw or serum ferritin ≤300 ng/mL, AE incidence before and after the first day of the event was summarized and adjusted for exposure duration.
Statistical analyses for the core have been reported previously . For the primary efficacy analysis, the proportion of patients who reached LIC <5 mg Fe/g dw by the end of the extension is presented with a 95 % confidence interval (Wilson CI) . For data analyses presented by average actual dose, patients were summarized by the dose category regardless of their treatment groups. Descriptive statistics were used to present efficacy analyses. Compliance was reported as planned dose taken = 100 × cumulative dose taken/cumulative planned dose.
Data were assessed by various groupings (core + extension and extension only) and core randomization arms. Primary analysis set for efficacy is the core + extension full analysis set (FAS) consisting of randomized patients in the core. Analyses for the core + extension FAS summarized data cumulatively from core randomization date. The extension FAS is randomized patients who entered the extension.
The core + extension safety set consists of all randomized patients who received ≥1 study drug dose. Analyses summarized all safety data cumulatively from the start date of the first dose in the core. Extension safety set was all randomized patients who entered the extension and received ≥1 deferasirox dose during the extension.
When reporting events by starting dose in the extension only, if the first actual deferasirox dose in the extension was <15 mg/kg/day, the patient was analyzed in the combined ≤10 mg/kg/day group; if the first actual dose in the extension was ≥15 mg/kg/day, the patient was analyzed in the 20 mg/kg/day group.
The study was sponsored by Novartis Pharma AG and designed by the sponsor in collaboration with the Study Steering Committee composed of expert hematologists in the thalassemia field. The sponsor conducted the statistical analysis. Authors had full access to data and actively participated in data interpretation and drafting/critical manuscript review, with the assistance of a medical writer funded by the sponsor. The corresponding author had final responsibility for manuscript content and decision to submit for publication.
Patient disposition and baseline demographics
Blood transfusions and exposure to treatment
For patients receiving deferasirox in the core and extension (n = 110), 88 (80.0 %) did not receive blood transfusions during the study. Twelve (10.9 %), five (4.5 %), two (1.8 %), one (0.9 %), and two (1.8 %) patients received 1, 2, 3, 4, or >4 transfusions, respectively.
Average actual dose and dose categories
Mean ± SD actual dose (mg/kg/day)
Median actual dose (mg/kg/day)
Dose categories (mg/kg/day), n (%)
>0– ≤ 7.5
Deferasirox core + extension (n = 110)
9.8 ± 3.6
Deferasirox extension (n = 82)
12.6 ± 4.5
Crossover extension (n = 48)
13.7 ± 4.6
For patients entering the extension phase, in the deferasirox extension group, 64 (78.0 %) patients were in the ≤10 mg/kg/day group and 18 (22.0 %) patients were in the 20 mg/kg/day group. In the crossover group, 27 (56.3 %) were in the ≤10 mg/kg/day and 21 (43.8 %) were in the 20 mg/kg/day groups.
Average actual dose by dose category is shown in Table 1. In the deferasirox extension group, average actual dose breakdown was similar to those who were switching from placebo to deferasirox. Medication compliance was high in the extension phase with 97.2 ± 7.0 % in the deferasirox extension group and 96.0 ± 8.1 % in the crossover extension group taking the planned dose.
In the extension phase, doses were decreased as a result of AEs in 19 (23.2 %) patients in the deferasirox extension group [main reason gastroenteritis (six patients)] and 18 (37.5 %) patients in the crossover extension group [main reason gastroenteritis (four patients)].
Effect of deferasirox on LIC and serum ferritin
In the deferasirox core + extension group, absolute change in LIC by average actual dose category showed a dose response, with the highest decreases seen in the higher dose groups. Mean ± SD change in LIC from baseline to month 24 was −4.4 ± 4.60, –6.6 ± 3.99, –10.0 ± 5.86, and −10.4 ± 11.53 in the >0 to <7.5 (n = 15), 7.5–12.5 (n = 47), >12.5–17.5 (n = 18), and >17.5 (n = 4) mg/kg/day groups, respectively.
At 24 months, the largest absolute decrease in LIC was seen in patients with the higher baseline LIC. Patients in the deferasirox core + extension group with a baseline LIC of ≤7 (n = 18), >7–15 (n = 57), and >15 mg Fe/g dw (n = 35) had a mean ± SD LIC reduction of −2.5 ± 1.16 (n = 10), –5.4 ± 2.66 (n = 45), and −11.4 ± 6.31 mg Fe/g dw (n = 29), respectively. The overall mean net iron excretion was 0.104 mg/kg/day; in patients with baseline LIC ≤7, 7–15, and >15 mg Fe/g dw, the mean iron excretion was 0.036, 0.078, and 0.166 mg/kg/day, respectively.
The percentage of patients achieving LIC <5 and <3 mg Fe/g dw continued to increase over 2 years. Of 166 patients enrolled, 29 (17.5 %) patients achieved LIC <5 mg Fe/g dw by the end of the core [15 (9.0 %) patients in the deferasirox 10 mg/kg/day group, nine (5.4 %) in the deferasirox 5 mg/kg/day group, and five (3.0 %) in the placebo group (apparent improvement in the placebo group attributable to MRI variability)] [9, 12]. By the end of the extension, the number of patients who had achieved LIC <5 mg Fe/g dw had increased to 64 [38.6 %; 43/110 (39.1 %; 95 % CI 30.5, 48.4) patients in the deferasirox core + extension group and 21/56 (37.5 %; 95 % CI 26.0, 50.6) patients in the placebo/deferasirox group]. Overall, six (3.6 %) patients achieved LIC <3 mg Fe/g dw by the end of the core study; this increased to 24 (14.5 %) by the end of the extension.
Twenty-four patients in the core + extension who stopped deferasirox as a result of achieving LIC <3 mg Fe/g dw or serum ferritin <100 ng/mL had a mean LIC at the time of stopping of 2.20 ± 0.49 mg Fe/g dw. These patients were followed up over an average duration of 257.8 days (range 162–362), and the last available LIC was 3.08 ± 1.74 mg Fe/g dw (n = 13), with an absolute change after stopping of +0.87 ± 1.36 (range −1.4–4.5).
Safety profile and laboratory parameters
Overall, the safety profile of deferasirox up to 2 years was consistent with that seen in the core study . Over the 2 years, investigator-assessed drug-related AEs were reported in 35 (31.8 %) patients; most common (>5 %) were diarrhea, nausea, and rash [all seven (6.4 %)].
For patients treated with deferasirox for up to 2 years, the number of patients with worsening or new AEs, regardless of study drug relationship, before and after the first measurement of LIC <5 mg Fe/g dw or serum ferritin ≤300 ng/mL (n = 43) was 36 (83.7 %; exposure-adjusted 36/45.2 years = 0.80/year) and 24 (55.8 %; exposure-adjusted 24/28.8 years = 0.83/year), respectively.
In the extension phase, AEs regardless of study drug relationship were reported in 69.5 % of patients in the deferasirox extension group (68.8 % and 72.2 % in the ≤10 and 20 mg/kg/day groups, respectively) and 81.3 % in the crossover group (85.2 % and 76.2 % in the ≤10 and 20 mg/kg/day groups, respectively). The most common AEs (>10 %) regardless of study drug relationship in all patients were upper respiratory tract infection (17.7 %), diarrhea (14.6 %), pyrexia (12.3 %), and upper abdominal pain (11.5 %).
Investigator-assessed drug-related AEs (≥3 overall) by starting dose in the extension
Deferasirox (extension study)
Crossover (extension study)
≤10 mg/kg/day (n = 64) n (%)
20 mg/kg/day (n = 18) n (%)
≤10 mg/kg/day (n = 27) n (%)
20 mg/kg/day (n = 21) n (%)
Upper abdominal pain
Increased blood creatinine
In the extension phase, one patient in the deferasirox ≤10 mg/kg/day extension group and one patient in the crossover 20 mg/kg/day extension group had an increase in ALT >5× ULN and >2× baseline on two consecutive visits (absolute values—106, 114 and 400, 298 U/L, respectively); both had abnormal extension baseline ALT (>ULN to ≤5× ULN). The crossover patient also had one aspartate aminotransferase (AST) value >5× ULN and >2× baseline (AST ≤ ULN at baseline). Deferasirox was interrupted and then restarted in both patients; the ALT and AST increases observed were transient. One additional patient experienced one AST value >5× ULN and >2× baseline in the deferasirox ≤10 mg/kg/day extension group (AST ≤ ULN at extension baseline). AST levels returned to normal without dose amendment or interruption. Elevated transaminases were also reported as AEs in the above patients.
Two patients (one patient in the deferasirox extension group and one in the crossover group) had serum creatinine increases >33 % above baseline and above ULN (106 μmol/L) on ≥2 consecutive visits while taking 20 mg/kg/day deferasirox (absolute values—120 and 114 μmol/L in the deferasirox extension patient and 112–142 μmol/L in the crossover patient). Both patients had normal serum creatinine at extension baseline. The deferasirox dose in the deferasirox extension group patient was reduced and the serum creatinine levels normalized. Elevated creatinine was also reported as an AE in this patient. In the patient in the crossover group, serum creatinine started improving after drug interruption (last value remained 114 μmol/L). This patient also developed creatinine clearance <60 mL/min at ≥2 consecutive visits. Creatinine clearance before crossing over to deferasirox was 69 mL/min and then it fluctuated from 40 to 58 mL/min.
One patient in the deferasirox extension group had creatinine clearance <60 mL/min at ≥2 consecutive visits (absolute values ranged from 54 to 59 mL/min) while taking 5 mg/kg/day. This patient had an extension baseline creatinine clearance <60 mL/min. The dose was not changed; at the next assessments, creatinine clearance ranged from 52 to 60 mL/min.
One patient in the crossover extension group had urinary protein/creatinine ratio >1.0 mg/mg at ≥2 consecutive values (absolute values ranged from 2.41 to 4.01) while taking 20 mg/kg/day. This patient had an abnormal urinary protein/creatinine ratio of >0.2 to ≤1 mg/mg at both core and extension baseline. After drug interruption and deferasirox reinstatement at 20 mg/kg/day, urinary protein/creatinine ratio returned to baseline values at the end of the extension.
Mean ± SD hemoglobin levels remained stable during the extension phase (all patients: extension baseline—78.2 ± 16.5 g/L, month 24—79.8 ± 16.7 g/L).
The THALASSA trial provides the largest dataset for iron chelation in NTDT to date, confirming preliminary findings of iron reduction in small studies/case reports [3, 4, 5, 6, 7, 8, 10, 11, 15]. The 1-year study established a treatment paradigm for iron-overloaded NTDT patients whereby chelation with deferasirox can be initiated when LIC exceeds 5 mg Fe/g dw and continued with a treatment goal of reducing LIC below a threshold associated with complications .
Following the randomized, placebo-controlled 1-year trial, we report here results from a 1-year extension phase, providing the longest assessment duration of any iron chelator in NTDT patients in a controlled trial setting. From the baseline LIC and serum ferritin reported , it is clear that despite no/limited transfusions, these patients have high iron burden, and this high burden has been associated with complications such as bone disease, thromboembolism, endocrinopathy, pulmonary hypertension, cerebrovascular and neuronal damage, liver fibrosis or cirrhosis, and increased risk of hepatocellular carcinoma (for overview see ).
Patients receiving deferasirox for one additional year after the core study continued to respond with a decrease in LIC and serum ferritin over 2 years. Overall, for patients receiving deferasirox for up to 2 years, approximately 40 % and 16 % reached LIC <5 and <3 mg Fe/g dw, respectively, with more patients reaching these targets during the second year, indicating that with appropriate dosing and continued treatment deferasirox continues to effectively remove iron.
Patients crossing over from placebo in the core to deferasirox in the extension also showed a considerable decrease in LIC and serum ferritin. These patients entered the extension with a higher extension baseline LIC, and received a higher actual average deferasirox dose during the extension, than those who received deferasirox during the core and continued with treatment in the extension. This has contributed to the large decrease in LIC seen in the crossover patients. This highlights the importance of monitoring iron burden and dose adjusting when necessary to achieve therapeutic goals.
The safety profile over 2 years of deferasirox treatment did not differ from that observed in the core 1-year study. The overall incidence of AEs and abnormal laboratory parameters were comparable in the extension and core phase . The safety profile did not appear to differ in the ≤10 and the 20 mg/kg/day dose groups in the extension phase. There was a gradual decrease in mean ALT over time, potentially indicating a decrease in iron-related hepatocellular injury. A slight increase in serum creatinine, gradual over 2 years, was observed as the average dose increased.
The number of patients with worsening or new AEs, regardless of drug relationship, whose LIC was <5 mg Fe/g dw or serum ferritin was ≤300 ng/mL did not appear to differ overall from that prior to achieving these levels, indicating that chelation to these levels may not adversely affect the number of worsening or new AEs.
A recent study revealed that patients with LIC >7 and >6 mg Fe/g dw, respectively, were more likely to have an already established vascular or endocrine/bone morbidity . Such information confirms the need to establish therapeutic LIC goals specific to NTDT, which are likely to differ from those already established in transfusion-dependent patients. New NTDT guidelines , information on the link between LIC and comorbidities  as well as data from large studies on chelation such as THALASSA allow some recommendations to be considered. Data from THALASSA suggest that deferasirox can be used to reduce iron burden in patients with LIC >5 mg Fe/g dw. Patients achieving LIC <3 mg Fe/g dw may be able to interrupt chelation therapy; it is important to reiterate that LIC assessment is the preferred option in NTDT patients, although serum ferritin can be used to guide initiation, monitoring, and interruption of chelation therapy . After patients reach the therapeutic target, the recommendation is to monitor them with LIC evaluation every 1–2 years if feasible, which will identify any patients whose LIC is approaching values of >5 mg Fe/g dw and hence would require reintroduction of iron chelation .
THALASSA is the longest controlled trial of iron chelation in NTDT; however, it will be of interest to observe patients over the longer term. In particular, it will be of interest to observe patients who interrupt their chelation because they achieved their therapeutic goals and to then determine when they need to be reintroduced to chelation therapy as their burden increases as they age.
In conclusion, THALASSA data confirm that deferasirox, with appropriate dosing, effectively reduces iron overload over 2 years with a manageable safety profile providing robust evidence to assist clinicians in managing iron overload in patients with NTDT.
This study was funded by Novartis Pharma AG. We thank Michelle Utton-Mishra, PhD, for medical editorial assistance. Financial support for medical editorial assistance was provided by Novartis Pharmaceuticals. For a full list of participating investigators and their affiliations please see electronic supplemental material.
Conflicts of interest
ATT reports receiving research funding and honoraria from Novartis Pharmaceuticals; JBP reports received research funding from Novartis Pharmaceuticals, being a member of an advisory committee and participating in a Novartis speaker’s bureau; VV received research grant support and lecture fees from Novartis Pharmaceuticals and research grant support from GPOLONE, Thailand, FerroKin Biosciences, and National Research University (NRU), Thailand; AK reports received honoraria and research funding from Novartis Pharmaceuticals and participating in a speaker’s bureau; SC, PS, and NS received research funding from Novartis Pharmaceuticals; RG received research grants and speaker’s honoraria from Novartis Pharmaceuticals; ZK received research grants and speaker’s honoraria from Novartis Pharmaceuticals; TL, JR, ZZ, and DH are full-time employees of Novartis Pharmaceuticals; MDC reports participating in a Novartis Pharmaceuticals speaker’s bureau.
Open Access This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.